



Curriculum Vitae Europass

Informazioni personali

Nome(i) / Cognome(i)

Massimiliano Bonifacio

Indirizzo lavorativo

Dipartimento di Ingegneria per la Medicina di Innovazione (DIMI), Università di Verona
UOC Ematologia, Policlinico G.B. Rossi, Azienda Ospedaliera Universitaria Integrata di Verona
P.le L.A.Scuro 10, 37134 Verona

E-mail

massimiliano.bonifacio@univr.it

Cittadinanza

italiana

Esperienza professionale

Date **16/12/2021 ad oggi**

Lavoro o posizione ricoperti

Professore di II fascia ai sensi dell'art.24 comma 5 della Legge 240/2010 (S.S.D. MED/15 Malattie del Sangue) presso Dipartimento di Medicina – Sezione di Ematologia (dal 1.3.2023 Dipartimento di Ingegneria per la Medicina di Innovazione), Università di Verona

Date **16/12/2018 – 15/12/2021**

Lavoro o posizione ricoperti

Ricercatore a tempo determinato con contratto di durata triennale ai sensi dell'art.24 comma 3 lettera b) (*Senior*) della Legge 240/2010 (S.S.D. MED/15 Malattie del Sangue) presso Dipartimento di Medicina – Sezione di Ematologia, Università di Verona

Date **16/12/2013 – 15/12/2018**

Lavoro o posizione ricoperti

Ricercatore a tempo determinato con contratto di durata triennale e successiva proroga biennale ai sensi dell'art.24 comma 3 lettera a) (*Junior*) della Legge 240/2010 (S.S.D. MED/15 Malattie del Sangue) presso Dipartimento di Medicina – Sezione di Ematologia, Università di Verona

Date **01/04/2012 – 15/12/2013**

Lavoro o posizione ricoperti

Titolare di assegno di ricerca dal titolo “ α -bisabololo: efficacia in cellule staminali leucemiche BCR-ABL+ e sinergismo con inibitori delle tirosin-chinasi” (area scientifico disciplinare MED/15 Malattie del Sangue) presso Dipartimento di Medicina – Sezione di Ematologia, Università di Verona

Date **01/03/2012 – 31/03/2012**

Lavoro o posizione ricoperti

Incarico retribuito per attività di valutazione e inserimento in data base di dati clinici e biologici di pazienti affetti da leucemia mieloide cronica presso UOC Ematologia dU – Azienda Ospedaliera Universitaria Integrata di Verona

Date **01/03/2008 – 28/02/2012**

Lavoro o posizione ricoperti

Titolare di assegno di ricerca dal titolo “Ruolo funzionale di CD30 nella regolazione immune: il cross-talk tra CD30 e CXCR4” (area scientifico disciplinare MED/15 Malattie del Sangue) presso Dipartimento di Medicina – Sezione di Ematologia, Università di Verona.

Attività clinica assistenziale

dal **10 giugno 2008 ad oggi** attività clinica assistenziale presso UOC Ematologia – Azienda Ospedaliera Universitaria Integrata di Verona, con particolare riferimento ai pazienti affetti da malattie mieloproliferative croniche:
– responsabile dell'Ambulatorio Malattie Mieloproliferative, attivo dal 16 aprile 2012
– componente dell'equipe multidisciplinare dell'Ambulatorio Integrato per la Mastocitosi

Istruzione e formazione

Date **03/12/2007**

Titolo della qualifica rilasciata

Diploma di specializzazione in Ematologia, Università di Verona

Date **28/10/2003**

Titolo della qualifica rilasciata

Diploma di laurea in Medicina e Chirurgia, Università di Verona

Capacità e competenze personaliMadrelingua(e) **italiana**

Altra(e) lingua(e)

Autovalutazione

Livello europeo (*)

inglese

Comprensione		Parlato		Scritto
Ascolto	Lettura	Interazione orale	Produzione orale	
B2	C1	B2	B2	C1

Attività didattica

- Didattica frontale di Malattie del Sangue nella scuola di Specializzazione di Ematologia e nella Scuola di Specializzazione di Medicina Interna dell'Università di Verona (dall'AA 2013-2014)
- Didattica pratica (tutorial) di Problem Based Learning / Problem Based Solving per gli studenti del Corso di Laurea magistrale a ciclo unico in Medicina e Chirurgia dell'Università di Verona (dall'AA 2015-2016)
- Titolare del modulo di insegnamento "Oncologia Ematologica" nel corso di Laurea in Ostetrica dell'Università di Verona (dall'AA 2017-2018)

Campi di interesse scientifico

- Leucemia Mieloide Cronica
- Leucemia Linfoblastica Acuta dell'Adulto
- Neoplasie Mieloproliferative
- Mastocitosi
- Immunoterapia

Esperienza in GCP clinical trials

- da dicembre 2005 sub-investigatore nei protocolli del gruppo cooperativo GIMEMA (CML e AL working parties)
- dal 1 ottobre 2014 Principal Investigator di oltre 100 protocolli nazionali e internazionali (studi di fase I-II-III-IV, profit e no profit) riguardanti le patologie di interesse scientifico

Partecipazione a società scientifiche e gruppi di lavoro

- Società Italiana di Ematologia (SIE) dal 2007
- Società Italiana di Ematologia Sperimentale (SIES) dal 2015
- European Competence Network on Mastocytosis (ECNM) dal 2017
- European Hematology Association (EHA) dal 2020
- Coordinatore della commissione Leucemia Mieloide Cronica della Rete Ematologica Veneta (REV) dal 2017
- Coordinatore di gruppi di lavoro dei progetti Campus ALL (dal 2017) e Campus CML (dal 2019)

Pubblicazioni (indici sintetici)

ORCID-ID: 0000-0003-0716-1686

Numero totale pubblicazioni: 183

H-index: 40

Numero totale citazioni: 6.921 (aggiornato a fine ottobre 2024, fonte Scopus)

Pubblicazioni (elenco analitico)

- Breccia M, Cucci R, Marsili G, Castagnetti F, Galimberti S, Izzo B, Sorà F, Soverini S, Messina M, Piciocchi A, **Bonifacio M**, Cilloni D, Iurlo A, Martinelli G, Rosti G, Stagno F, Fazi P, Vignetti M, Pane F. Deep Molecular Response Rate in Chronic Phase Chronic Myeloid Leukemia: Eligibility to Discontinuation Related to Time to Response and Different Frontline TKI in the Experience of the Gimema Labnet CML National Network. *Clin Lymphoma Myeloma Leuk*. 2024 Sep 7:S2152-2650(24)01802-0. Epub ahead of print.
- Bucelli C, Capodanno I, Miggiano MC, Cavazzini F, Crescenzi SL, Russo S, Carmosino I, Annunziata M, Sorà F, **Bonifacio M**, Luciano L, Caocci G, Loggisci G, Elena C, Lunghi F, Mullai R, Attolico I, Binotto G, Crisà E, Sportoletti P, Di Veroli A, Scortechini AR, Leporace AP, Maggi A, Crugnola M, Stagno F, Sancetta R, Murgano P, Rapezzi D, Luzzi D, Vincelli DI, Galimberti S, Bocchia M, Fava C, Malato A, Abruzzese E, Saglio G, Specchia G, Breccia M, Iurlo A, Tiribelli M, Latagliata R. Choice of Frontline Tyrosine-Kinase Inhibitor and Early Events in Very Elderly Patients With Chronic Myeloid Leukemia in Chronic Phase: A "Campus CML" Study. *Eur J Haematol*. 2024 Sep 12. Epub ahead of print.
- Lazarotto D, Cerrano M, Papayannidis C, Chiaretti S, Mosna F, Fracchiolla N, Zappasodi P, Imbergamo S, Del Principe MI, Lunghi M, Lussana F, Piccini M, Fumagalli M, Dargenio M, Salutati P, Forghieri F, Da Molin TG, **Bonifacio M**, Olivi M, Giglio F, Trappolini S, Leoncin M, Mule A, Delia M, Pasciolla C, Grimaldi F, Cambo B, Santoro L, Guolo F, Minetto P, Defina M, Chiusolo P, Fanin M, Mauro E, Aprile L, Mazzone C, Trastulli F, Ciccone M, De Gobbi M, Cignetti A, De Bellis E, Mancini V, Piciocchi A, Vignetti M, Marsili G, Starza ID, Fanin R, Luppi M, Ferrara F, Pizzolo G, Bassan R, Foa R, Candoni A. Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a Campus ALL study. *Haematologica*. 2024 Aug 15. Epub ahead of print.
- Palandri F, Elli EM, Morsia E, Benevolo G, Tiribelli M, Beggiato E, **Bonifacio M**, Farina M, Martino B, Caocci G, Pugliese N, Tieghi A, Crugnola M, Binotto G, Cavazzini F, Abruzzese E, Iurlo A, Isidori A, Bosi C, Guglielmana V, Venturi M, Dedola A, Loffredo M, Fontana G, Duminuco A, Moiola A, Tosoni L, Scalzulli E, Cattaneo D, Lemoli RM, Cilloni D, Bocchia M, Pane F, Heidel FH, Vianelli N, Cavo M, Palumbo GA, Branzanti F, Breccia M. Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study. *Cancer*. 2024 Jul 30. Epub ahead of print.
- Tanasi I, Crosera L, Taus F, Orsolini G, Adami G, Olivieri F, Bernardelli A, Bonadonna P, Nalin F, Sella S, Giannini S, Liu Y, Mannelli F, Vanderwert F, **Bonifacio M**, Krampera M, Rossini M, Lyons JJ, Zanotti R. Underlying systemic mastocytosis in patients with unexplained osteoporosis: score proposal. *Bone*. 2024;186:117141.
- Tiribelli M, Morelli G, **Bonifacio M**. Advances in pharmacotherapy for myelofibrosis: what is the current state of play? *Expert Opin Pharmacother*. 2024;25(6):743-754.
- Lübke J, Schmid A, Christen D, Oude Elberink HNG, Span LFR, Niedoszytko M, Gorska A, Lange M, Gleixner KV, Hadzijusufovic E, Stefan A, Angelova-Fischer I, Zanotti R, **Bonifacio M**, Bonadonna P, Shoumariyeh K, von Bubnoff N, Müller S, Perkins C, Elena C, Malcovati L, Hagglund H, Mattsson M, Parente R, Varkonyi J, Fortina AB, Caroppo F, Brockow K, Zink A, Breynaert C, Leven T, Yavuz AS, Doubek M, Sabato V, Schug T, Hartmann K, Triggiani M, Gotlib J, Hermine O, Arock M, Kluin-Nelemans HC, Panse J, Sperr WR, Valent P, Reiter A, Schwaab J. Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM. *Blood Adv*. 2024;8(11):2890-2900.
- Bonifacio M**, Scaffidi L, Miggiano MC, Facchinelli D, Tosoni L, Pezone S, Griguolo D, Ciotti G, Danini M, Bernardelli A, Bresciani R, Cavarro M, Crosera L, De March E, Dell'Eva M, Dorotea L, Frison L, Furlani L, Ganesello I, Lovato E, Marchetti E, Morelli G, Mullai R, Pizzano U, Zoletto S, Fanin R, Krampera M, Trentin L, Calistri E, Carli G, Binotto G, Tiribelli M. A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements. *Blood Cancer J*. 2024;14(1):53.
- Palandri F, Auteri G, Abruzzese E, Caocci G, **Bonifacio M**, Mendicino F, Latagliata R, Iurlo A, Branzanti F, Garibaldi B, Trawinska MM, Cattaneo D, Krampera M, Mulas O, Martino EA, Cavo M, Vianelli N, Impera S, Efficace F, Heidel F, Breccia M, Elli EM, Palumbo GA. Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the "RAMP" Italian multicenter prospective study. *Ann Hematol*. 2024;103(6):1931-1940.
- Malagola M, Iurlo A, Bucelli C, Abruzzese E, **Bonifacio M**, Stagno F, Binotto G, D'Adda M, Lunghi M, Crugnola M, Ferrari ML, Lunghi F, Castagnetti F, Rosti G, Lemoli RM, Sancetta R, Coppi MR, Corsetti MT, De Gobbi M, Romano A, Tiribelli M, Russo Rossi A, Russo S, Defina M, Farina M, Bernardi S, Butturini G, Pellizzeri S, Roccaro AM, Russo D. The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan. *Clin Lymphoma Myeloma Leuk*. 2024;24(5):323-331.
- Barbui T, Vannucchi AM, De Stefano V, Carobbio A, Ghirardi A, Carioli G, Masciulli A, Rossi E, Ciceri F, **Bonifacio M**, Iurlo A, Palandri F, Benevolo G, Pane F, Ricco A, Carli G, Caramella M, Rapezzi D, Musolino C, Siragusa S, Rumi E, Patriarca A, Cascavilla N, Mora B, Cacciola E, Mannarelli C, Loscocco GG, Guglielmelli P, Gesullo F, Betti S, Lunghi F, Scaffidi L, Bucelli C, Vianelli N, Bellini M, Finazzi MC, Tognoni G, Rambaldi A. Ropgeinterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. *NEJM Evid*. 2023 Jun;2(6):EVID0a2200335.

Pubblicazioni (continua)

Palandri F, Palumbo GA, Benevolo G, Iurlo A, Elli EM, Abruzzese E, Polverelli N, Tiribelli M, Auteri G, Tieghi A, Caocci G, Binotto G, Cavazzini F, Branzanti F, Beggiato E, Miglino M, Bosi C, Crugnola M, Bocchia M, Martino B, Pugliese N, Scaffidi L, Venturi M, Duminuco A, Isidori A, Cattaneo D, Krampera M, Pane F, Cilloni D, Semenzato G, Lemoli RM, Cuneo A, Trawinska MM, Vianelli N, Cavo M, **Bonifacio M***, Breccia M*. Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy. *Cancer*. 2024;130(8):1270-1280.

**equal co-last authors*

Foà R, Bassan R, Elia L, Piciocchi A, Soddu S, Messina M, Ferrara F, Lunghi M, Mulè A, **Bonifacio M**, Fracchiolla N, Salutati P, Fazi P, Guarini A, Rambaldi A, Chiaretti S. Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL. *J Clin Oncol*. 2024;42(8):881-885.

Barbui T, Carobbio A, De Stefano V, Alvarez-Larran A, Ghirardi A, Carioli G, Fenili F, Rossi E, Ciceri F, **Bonifacio M**, Iurlo A, Palandri F, Benevolo G, Pane F, Ricco A, Carli G, Caramella M, Rapezzi D, Musolino C, Siragusa S, Rumi E, Patriarca A, Cascavilla N, Mora B, Cacciola E, Calabresi L, Loscocco GG, Guglielmelli P, Gesullo F, Betti S, Ramundo F, Lunghi F, Scaffidi L, Bucelli C, Cattaneo D, Vianelli N, Bellini M, Finazzi MC, Tognoni G, Rambaldi A, Vannucchi AM. Ropgeinterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes. *Ann Hematol*. 2024;103(2):437-442.

Mulas O, Abruzzese E, Luciano L, Iurlo A, Attolico I, Castagnetti F, Galimberti S, **Bonifacio M**, Annunziata M, Gozzini A, Orlandi EM, Stagno F, Binotto G, Pregno P, Fozza C, Loi M, Trawinska MM, De Gregorio F, Cattaneo D, Albano F, Iezza M, Barate C, Scaffidi L, Elena C, Gai V, Scalzulli E, Breccia M, La Nasa G, Caocci G. The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib. *Ann Hematol*. 2024;103(2):427-436.

Mannelli F, Crupi F, Zanotti R, Pagano L, Rapezzi D, Tanasi I, Criscuolo M, **Bonifacio M**, Fresa A, Guglielmelli P, Vannucchi AM. The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis. *Ther Adv Hematol*. 2023;14:20406207231205643.

Palandri F, Palumbo GA, **Bonifacio M**, Elli EM, Tiribelli M, Auteri G, Trawinska MM, Polverelli N, Benevolo G, Tieghi A, Cavalca F, Caocci G, Beggiato E, Binotto G, Cavazzini F, Miglino M, Bosi C, Crugnola M, Bocchia M, Martino B, Pugliese N, Venturi M, Isidori A, Cattaneo D, Krampera M, Pane F, Cilloni D, Semenzato G, Lemoli RM, Cuneo A, Abruzzese E, Branzanti F, Vianelli N, Cavo M, Heidel F, Iurlo A, Breccia M. A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis. *Cancers (Basel)*. 2023;15(20):5027.

Efficace F, Cottone F, Yanez B, Kota V, Castagnetti F, Caocci G, **Bonifacio M**, Patriarca A, Capodanno I, Miggiano MC, Tiribelli M, Breccia M, Luciano L, Gai V, Iurlo A, Abruzzese E, Fava C, Dinner S, Altman JK, Rosti G, Cortes J, Vignetti M, Cella D. Patient-reported symptom monitoring and adherence to therapy in patients with

Malfona F, Tanasi I, Piccini M, Papayannidis C, Federico V, Mancini V, Roncoroni E, Todisco E, Bianchi S, Ciotti G, Chiusolo P, Gentile M, Gianfelici V, Giglio F, Malagola M, Mulè A, Saraceni F, Vetro C, Zallio F, Cappelli LV, Pizzolo G, Foà R, **Bonifacio M***, Chiaretti S*. BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study. *Haematologica*. 2024;109(3):988-993.

**equal co-last authors*

Fracchiolla NS, Sciumè M, Papayannidis C, Vitale A, Chiaretti S, Annunziata M, Giglio F, Salutati P, Forghieri F, Lazzarotto D, Lunghi M, Imovilli A, Scappini B, **Bonifacio M**, Dargenio M, Gurrieri C, Todisco E, Defina M, Del Principe MI, Zappasodi P, Cerrano M, Santoro L, Tagliaferri E, Barozzi E, De Roberto P, Canzi M, Buzzatti E, Sartor C, Passamonti F, Foà R, Curti A. Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study. *Cancers (Basel)*. 2023;15(18):4623.

Ocadlikova D, Lussana F, Fracchiolla N, **Bonifacio M**, Santoro L, Delia M, Chiaretti S, Pasciolla C, Cignetti A, Forghieri F, Grimaldi F, Corradi G, Zannoni L, De Propriis S, Borleri GM, Tanasi I, Vadaekolathu J, Rutella S, Guarini AR, Foà R, Curti A; Campus ALL. Blinatumomab differentially modulates peripheral blood and bone marrow immune cell repertoire: A Campus ALL study. *Br J Haematol*. 2023;203(4):637-650.

Palandri F, Rossi E, Auteri G, Breccia M, Paglia S, Benevolo G, Elli EM, Cavazzini F, Binotto G, Tieghi A, Tiribelli M, Heidel FH, **Bonifacio M**, Pugliese N, Caocci G, Crugnola M, Mendicino F, D'Addio A, Tomassetti S, Martino B, Polverelli N, Ceglie S, Mazzoni C, Mullai R, Ripamonti A, Garibaldi B, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Vianelli N, Palumbo GA, Andriani A, Cavo M, Latagliata R, De Stefano V. Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study. *Cancers (Basel)*. 2023;15(14):3706.

Mazzera L, Abeltino M, Lombardi G, Cantoni AM, Jottini S, Corradi A, Ricca M, Rossetti E, Armando F, Peli A, Ferrari A, Martinelli G, Scupoli MT, Visco C, **Bonifacio M**, Ripamonti A, Gambacorti-Passerini C, Bonati A, Perris R, Lunghi P. MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia. *Leukemia*. 2023;37(8):1671-1685.

Pubblicazioni (continua)

- Tiribelli M, Latagliata R, Breccia M, Capodanno I, Miggiano MC, Cavazzini F, Bucelli C, Attolico I, Crescenzi SL, Russo S, Annunziata M, Sorà F, **Bonifacio M**, Mulas O, Loglisci G, Maggi A, Binotto G, Crisà E, Scortechini AR, Leporace AP, Sancetta R, Murgano P, Abruzzese E, Stagno F, Rapezzi D, Luzi D, Vincelli I, Bocchia M, Fava C, Malato A, Crugnola M, Pizzuti M, Lunghi F, Galimberti S, Dalmazzo M, Fanin R, Scalzulli E, Foà R, Iurlo A, Saglio G, Specchia G. Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML. *Cancer*. 2023;129(17):2637-2644.
- Bassan R, Chiaretti S, Della Starza I, Spinelli O, Santoro A, Paoloni F, Messina M, Elia L, De Propriis MS, Scattolin AM, Audisio E, Marbello L, Borlenghi E, Zappasodi P, Mauro E, Martinelli G, Mattei D, Fracchiolla N, Bocchia M, De Fabritiis P, **Bonifacio M**, Candoni A, Cassibba V, Di Bartolomeo P, Latte G, Trappolini S, Guarini A, Vitale A, Fazi P, Piciocchi A, Rambaldi A, Foà R. Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial. *Blood Adv*. 2023;7(16):4448-4461.
- Palandri F, Elli EM, Auteri G, **Bonifacio M**, Benevolo G, Heidel FH, Paglia S, Trawinska MM, Bosi C, Rossi E, Tiribelli M, Tieghi A, Iurlo A, Polverelli N, Caocci G, Binotto G, Cavazzini F, Beggato E, Cilloni D, Tatarelli C, Mendicino F, Miglino M, Bocchia M, Crugnola M, Mazzoni C, Romagnoli AD, Rindone G, Ceglie S, D'Addio A, Santoni E, Cattaneo D, Bartoletti D, Lemoli RM, Krampere M, Cuneo A, Semenzato GC, Latagliata R, Abruzzese E, Vianelli N, Cavo M, Andriani A, De Stefano V, Palumbo GA, Breccia M. Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib. *Blood Cancer J*. 2023;13(1):65.
- Iurlo A, Cattaneo D, Consonni D, Castagnetti F, Miggiano MC, Binotto G, **Bonifacio M**, Rege-Cambrin G, Tiribelli M, Lunghi F, Gozzini A, Pregno P, Abruzzese E, Capodanno I, Bucelli C, Pizzuti M, Artuso S, Iezza M, Scalzulli E, La Barba G, Maggi A, Russo S, Elena C, Scortechini AR, Tafuri A, Latagliata R, Caocci G, Bocchia M, Galimberti S, Luciano L, Fava C, Foà R, Saglio G, Rosti G, Breccia M. Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study. *Front Pharmacol*. 2023;14:1154377.
- Lazarotto D, Tanasi I, Vitale A, Piccini M, Dargenio M, Giglio F, Forghieri F, Fracchiolla N, Cerrano M, Todisco E, Papayannidis C, Leoncin M, Defina M, Guolo F, Pasciolla C, Delia M, Chiusolo P, Mulè A, Candoni A, **Bonifacio M**, Pizzolo G, Foà R. Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia treated with acute myeloid leukemia-like or acute lymphoblastic leukemia-like chemotherapy and impact of allogeneic stem cell transplantation: a Campus ALL study. *Ann Hematol*. 2023;102(5):1099-1109.
- Palandri F, Breccia M, Mazzoni C, Auteri G, Elli EM, Trawinska MM, Polverelli N, Tiribelli M, Benevolo G, Iurlo A, Tieghi A, Heidel FH, Caocci G, Beggato E, Binotto G, Cavazzini F, Miglino M, Bosi C, Crugnola M, Bocchia M, Martino B, Pugliese N, Biondo M, Venturi M, Scaffidi L, Isidori A, Cattaneo D, Krampere M, Pane F, Cilloni D, Semenzato G, Lemoli RM, Cuneo A, Abruzzese E, Bartoletti D, Paglia S, Vianelli N, Cavo M, **Bonifacio M***, Palumbo GA*. Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome. *Cancer*. 2023;129(11):1704-1713
- *equal co-last authors*
- Mancini M, Monaldi C, De Santis S, Papayannidis C, Rondoni M, Sartor C, Bruno S, Pagano L, Criscuolo M, Zanotti R, **Bonifacio M**, Tosi P, Arock M, Valent P, Cavo M, Soverini S. SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted. *Biomark Res*. 2023;11(1):29.
- Breccia M, Vinchi F, **Bonifacio M**, Binotto G, Zheng G. Editorial: Risk-stratification in myelodysplastic syndromes. *Front Oncol*. 2022;12:1095847.
- Lübke J, Schwaab J, Christen D, Elberink HO, Span B, Niekoszytko M, Gorska A, Lange M, Gleixner KV, Hadzijušufovic E, Solomianyi O, Angelova-Fischer I, Zanotti R, **Bonifacio M**, Bonadonna P, Shoumariyeh K, von Bubnoff N, Müller S, Perkins C, Elena C, Malcovati L, Hagglund H, Mattsson M, Parente R, Varkonyi J, Fortina AB, Caroppo F, Zink A, Brockow K, Breynaert C, Bullens D, Yavuz AS, Doubek M, Sabato V, Schug T, Niederwieser D, Hartmann K, Triggiani M, Gotlib J, Hermine O, Arock M, Kluin-Nelemans HC, Panse J, Sperr WR, Valent P, Reiter A, Jawhar M. Prognostic Impact of Organomegaly in Mastocytosis: An Analysis of the European Competence Network on Mastocytosis. *J Allergy Clin Immunol Pract*. 2023;11(2):581-590.e5.
- Barbui T, Carobbio A, Ghirardi A, Iurlo A, De Stefano V, Sobas MA, Rumi E, Elli EM, Lunghi F, Gasior Kabat M, Cuevas B, Guglielmelli P, **Bonifacio M**, Marchetti M, Alvarez-Larran A, Fox L, Bellini M, Daffini R, Benevolo G, Carreno-Tarragona G, Patriarca A, Al-Ali HK, Andrade-Campos MMM, Palandri F, Harrison C, Foncillas MA, Osorio S, Koschmieder S, Magro Mazo E, Kiladjian JJ, Bolaños Calderón E, Heidel FH, Quiroz Cervantes K, Griesshammer M, Garcia-Gutierrez V, Sanchez AM, Hernandez-Boluda JC, Lopez Abadia E, Carli G, Sagues Serrano M, Kusec R, Xicoy Cirici B, Guenova M, Navas Elorza B, Angona A, Cichocka E, Kulikowska de Nalęcz A, Cattaneo D, Bucelli C, Betti S, Borsani O, Cavalca F, Carbonell S, Curto-Garcia N, Benajiba L, Rambaldi A, Vannucchi AM. Breakthrough infections in MPN-COVID vaccinated patients. *Blood Cancer J*. 2022;12(11):154.

Pubblicazioni (continua)

- Dargenio M*, **Bonifacio M***, Chiaretti S, Vitale A, Fracchiolla NS, Papayannidis C, Giglio F, Salutati P, Audisio E, Scappini B, Zappasodi P, Defina M, Forghieri F, Scattolin AM, Todisco E, Lunghi M, Guolo F, Del Principe MI, Annunziata M, Lazzarotto D, Cedrone M, Pasciolla C, Imovilli A, Tanasi I, Trappolini S, Cerrano M, La Starza R, Krampera M, Di Renzo N, Candoni A, Pizzolo G, Ferrara F, Foà R. Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front-line with paediatric-inspired regimens: A retrospective multicentre Campus ALL study. *Br J Haematol.* 2023;200(4):440-450.
*equal co-first authors
- Palumbo GA, Breccia M, Barattè C, **Bonifacio M**, Elli EM, Iurlo A, Pugliese N, Rossi E, Guglielmelli P, Palandri F. Management of polycythemia vera: A survey of treatment patterns in Italy. *Eur J Haematol.* 2023;110(2):161-167.
- Di Giusto S, Toffoletti E, **Bonifacio M**, Binotto G, Miggiano MC, Calistri E, Stulle M, Ermacora A, Stella R, Scaffidi L, D'Amore F, Scotton G, Griguolo D, De Matteis G, Bertorelle R, Krampera M, Semenzato G, Fanin R, Damiani D, Tiribelli M. BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment-free remission: A study from the "GRUPPO TRIVENETO LMC". *Cancer Med.* 2023;12(3):3180-3184.
- Defina M, Lazzarotto D, Guolo F, Minetto P, Fracchiolla NS, Giglio F, Forghieri F, Vitale A, Chiaretti S, Papayannidis C, Piccini M, Mulè A, Bocchia M, Leoncin M, Gurrieri C, Aprile L, Lunghi M, **Bonifacio M**, Pasciolla C, Cerrano M, Fumagalli M, Foà R, Candoni A. Levocarnitine supplementation for asparaginase-induced hepatotoxicity in adult acute lymphoblastic leukemia patients: A multicenter observational study of the campus all group. *Leuk Res.* 2022;122:106963.
- Barbui T, Carobbio A, Ghirardi A, Iurlo A, Sobas MA, Elli EM, Rumi E, De Stefano V, Lunghi F, Marchetti M, Daffini R, Gasior Kabat M, Cuevas B, Fox ML, Andrade-Campos MM, Palandri F, Guglielmelli P, Benevolo G, Harrison C, Foncillas MA, **Bonifacio M**, Alvarez-Larran A, Kiladjian JJ, Bolaños Calderón E, Patriarca A, Quiroz Cervantes K, Griesshammer M, Garcia-Gutierrez V, Marin Sanchez A, Magro Mazo E, Carli G, Hernandez-Boluda JC, Osorio S, Carreno-Tarragona G, Sagues Serrano M, Kusec R, Navas Elorza B, Angona A, Xicoy Cirici B, Lopez Abadia E, Koschmieder S, Cattaneo D, Bucelli C, Cichocka E, de Nalęcz AK, Cavalca F, Borsani O, Betti S, Bellini M, Curto-Garcia N, Rambaldi A, Vannucchi AM. Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19. *Am J Hematol.* 2022;97(12):E470-E473.
- Boni C*, **Bonifacio M***, Vezzalini M, Scaffidi L, Tomasello L, Parker LL, Boscarino D, Paladin D, Krampera M, Sorio C. Successful Preservation of Native BCR::ABL1 in Chronic Myeloid Leukemia Primary Leukocytes Reveals a Reduced Kinase Activity. *Front Oncol.* 2022 8;12:904510.
*equal co-first authors
- Calzetti F, Finotti G, Tamassia N, Bianchetto-Aguilera F, Castellucci M, Canè S, Lonardi S, Cavallini C, Matte A, Gasperini S, Signoretti I, Benedetti F, **Bonifacio M**, Vermi W, Ugel S, Bronte V, Tecchio C, Scapini P, Cassatella MA. CD66b-CD64dimCD115- cells in the human bone marrow represent neutrophil-committed progenitors. *Nat Immunol.* 2022 May;23(5):679-691.
- Chiaretti S*, **Bonifacio M***, Agrippino R, Giglio F, Annunziata M, Curti A, Principe MID, Salutati P, Sciumè M, Delia M, Armenio M, Mancini V, Mulè A, Grimaldi F, Rege-Cambrin G, Santoro L, Lussana F, Chiusolo P, Pasciolla C, Scattolin AM, Cerrano M, Ciccone M, Defina M, Forghieri F, Mazzone C, Piccini M, Ferrara F, Pizzolo G, Foà R. COVID-19 infection in acute lymphoblastic leukemia over 15 months of the pandemic. A Campus ALL report. *Haematologica.* 2022;107(8):1955-1959.
*equal co-first authors
- Palandri F, Bartoletti D, Iurlo A, **Bonifacio M**, Abruzzese E, Caocci G, Elli EM, Auteri G, Tiribelli M, Polverelli N, Miglino M, Heidel FH, Tieghi A, Benevolo G, Beggiato E, Fava C, Cavazzini F, Pugliese N, Binotto G, Bosi C, Martino B, Crugnola M, Ottaviani E, Micucci G, Trawinska MM, Cuneo A, Bocchia M, Krampera M, Pane F, Lemoli RM, Cilloni D, Vianelli N, Cavo M, Palumbo GA, Breccia M. Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis. *Cancer.* 2022;128(13):2449-2454.
- Iurlo A, Cattaneo D, Artuso S, Consonni D, Abruzzese E, Binotto G, Bocchia M, **Bonifacio M**, Castagnetti F, Galimberti S, Gozzini A, Iezza M, Latagliata R, Luciano L, Maggi A, Miggiano MC, Pugno P, Rege-Cambrin G, Russo S, Scortechini AR, Tafuri A, Tiribelli M, Fava C, Rosti G, Foa R, Breccia M, Saglio G. Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study. *Front Oncol.* 2022;12:839915.
- Elli EM, Di Veroli A, Bartoletti D, Iurlo A, Carmosino I, Benevolo G, Abruzzese E, **Bonifacio M**, Bergamaschi M, Polverelli N, Caramella M, Cilloni D, Tiribelli M, Pugliese N, Caocci G, Crisà E, Porri R, Markovic U, Renzo R, Auteri G, Cattaneo D, Trawinska MM, Scaffidi L, Biale L, Bucelli C, Breccia M, Gambacorti-Passerini C, Palumbo GA, Latagliata R, Palandri F. Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study. *Br J Haematol.* 2022;197(2):190-200.
- Bonifacio M**, Papayannidis C, Lussana F, Fracchiolla N, Annunziata M, Sica S, Delia M, Foà R, Pizzolo G, Chiaretti S. Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. *Front Oncol.* 2022;11:804714.

Pubblicazioni (continua)

Barbui T, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Carioli G, Sobas MA, Elli EM, Rumi E, De Stefano V, Lunghi F, Marchetti M, Daffini R, Gasior Kabat M, Cuevas B, Fox ML, Andrade-Campos MM, Palandri F, Guglielmelli P, Benevolo G, Harrison C, Foncillas MA, **Bonifacio M**, Alvarez-Larran A, Kiladjian JJ, Bolaños Calderón E, Patriarca A, Quiroz Cervantes K, Griessammer M, Garcia-Gutierrez V, Marin Sanchez A, Magro Mazo E, Ruggeri M, Hernandez-Boluda JC, Osorio S, Carreno-Tarragona G, Sagues Serrano M, Kusec R, Navas Elorza B, Angona A, Xicoy Cirici B, Lopez Abadia E, Koschmieder S, Cattaneo D, Bucelli C, Cichocka E, Masternak Kulikowska de Nalecz A, Cavalca F, Borsani O, Betti S, Benajiba L, Bellini M, Curto-Garcia N, Rambaldi A, Vannucchi AM. Second versus first wave of COVID-19 in patients with MPN. *Leukemia*. 2022;36(3):897-900.

Cerrano M, **Bonifacio M**, Olivi M, Curti A, Malagola M, Dargenio M, Scattolin AM, Papayannidis C, Forghieri F, Gurrieri C, Tanasi I, Zappasodi P, La Starza R, Fracchiolla NS, Chiusolo P, Giaccone L, Del Principe MI, Giglio F, Defina M, Favre C, Rizzari C, Castella B, Pizzolo G, Ferrara F, Chiaretti S, Foà R. Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study. *Haematologica*. 2022;107(4):996-999.

Zanotti R*, **Bonifacio M***, Isolani C, Tanasi I, Crosera L, Olivieri F, Orsolini G, Schena D, Bonadonna P. A Multidisciplinary Diagnostic Approach Reveals a Higher Prevalence of Indolent Systemic Mastocytosis: 15-Years' Experience of the GISM Network. *Cancers (Basel)*. 2021;13(24):6380.

*equal co-first authors

Zanotti R, Tanasi I, Crosera L, **Bonifacio M**, Schena D, Orsolini G, Mastropaolo F, Tebaldi M, Olivieri E, Bonadonna P. Systemic Mastocytosis: Multidisciplinary Approach. *Mediterr J Hematol Infect Dis*. 2021;13(1):e2021068.

Castagnetti F, Binotto G, Capodanno I, Billio A, Calistri E, Cavazzini F, Crugnola M, Gozzini A, Gugliotta G, Krampera M, Lucchesi A, Merli A, Miggiano MC, Minotto C, Poggiaspalla M, Salvucci M, Scappini B, Tiribelli M, Trabacchi E, Rosti G, Galimberti S, **Bonifacio M**. Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools. *Target Oncol*. 2021;16(6):823-838.

Martinelli G, Papayannidis C, Piciocchi A, Robustelli V, Soverini S, Terragna C, Marconi G, Lemoli RM, Guolo F, Fornaro A, Lunghi M, de Fabritiis P, Candoni A, Sella C, Simonetti F, Bocchia M, Vitale A, Frison L, Tedeschi A, Cuneo A, **Bonifacio M**, Martelli MP, D'Ardia S, Trappolini S, Tosi P, Galieni P, Fabbiano F, Abbenante MC, Granier M, Zhu Z, Wang M, Sartor C, Paolini S, Cavo M, Foà R, Fazi P, Vignetti M, Baccarani M. INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia. *Blood Adv*. 2022;6(6):1742-1753.

Breccia M, Abruzzese E, Accurso V, Attolico I, Barulli S, Bergamaschi M, Binotto G, Bocchia M, **Bonifacio M**, Caocci G, Capodanno I, Castagnetti F, Cavazzini F, Crisà E, Crugnola M, Stella De Candia M, Elena C, Fava C, Galimberti S, Gozzini A, Gugliotta G, Intermesoli T, Iurlo A, La Barba G, Latagliata R, Leonetti Crescenzi S, Levato L, Loggisci G, Lucchesi A, Luciano L, Lunghi F, Luzi D, Malato A, Cristina Miggiano M, Pizzuti M, Pregno P, Rapezzi D, Rege-Cambrin G, Rosti G, Russo S, Sancetta R, Rita Scortechini A, Sorà F, Sportoletti P, Stagno F, Tafuri A, Tiribelli M, Foà R, Saglio G. COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. *Br J Haematol*. 2022;196(3):559-565.

Zanotti R, **Bonifacio M***, Lucchini G, Sperr WR, Scaffidi L, van Anrooij B, Oude Elberink HN, Rossignol J, Hermine O, Gorska A, Lange M, Hadzijusufovic E, Miething C, Müller S, Perkins C, Shomali W, Elena C, Illerhaus A, Jawhar M, Parente R, Caroppo F, Solomianyi O, Zink A, Mattsson M, Yavuz AS, Panse J, Varkonyi J, Doubek M, Sabato V, Breynaert C, Vucinic V, Schug T, Hägglund H, Wortmann F, Brockow K, Angelova-Fischer I, Belloni Fortina A, Triggiani M, Reiter A, Hartmann K, Malcovati L, Gotlib J, Shoumariyeh K, Niekoszko M, Arock M, Kluin-Nelemans HC, Bonadonna P, Valent P. Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis. *Leukemia*. 2022;36(2):516-524.

*corresponding author

Specchia G, Pregno P, Breccia M, Castagnetti F, Monagheddu C, **Bonifacio M**, Tiribelli M, Stagno F, Caocci G, Martino B, Luciano L, Pizzuti M, Gozzini A, Scortechini AR, Albano F, Bergamaschi M, Capodanno I, Patriarca A, Fava C, Rege-Cambrin G, Sorà F, Galimberti S, Bocchia M, Binotto G, Reddiconto G, DiTonno P, Maggi A, Sanpaolo G, De Candia MS, Giai V, Abruzzese E, Miggiano MC, La Barba G, Pietrantuono G, Guella A, Levato L, Mulas O, Saccona F, Rosti G, Musto P, Di Raimondo F, Pane F, Baccarani M, Saglio G, Ciccone G. Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network. *Front Oncol*. 2021;11:739171.

Stagno F, Breccia M, Annunziata M, Trawinska MM, Iurlo A, Sgherza N, Fava C, Gozzini A, Luciano L, Carmosino I, **Bonifacio M**, Sorà F, Leonetti Crescenzi S, Crugnola M, Gugliotta G, Galimberti S, Bucelli C, Colafigli G, Feo C, Tiribelli M, Mauro E, Russo Rossi A, Guarini A, Abruzzese E, Rosti G, Di Raimondo F, Latagliata R. Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study. *Acta Oncol*. 2021;60(11):1527-1533.

Pubblicazioni (continua)

Bonifacio M, Tiribelli M, Miggiano MC, Abruzzese E, Binotto G, Scaffidi L, Cordioli M, Damiani D, Di Bona E, Trawinska MM, Tanasi I, Dubbini MV, Velotta V, Ceccarelli G, Pierdomenico E, Lo Schirico M, Semenzato G, Ruggeri M, Fanin R, Tacconelli E, Pizzolo G, Krampera M. The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population. *Cancer Med.* 2021;10(18):6310-6316.

Bonifacio M, Maheshwari V, Tran D, Agostoni G, Filioussi K, Viana R. Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy. *Pharmacoecon Open.* 2022;6(1):95-104.

Barbui T, Iurlo A, Masciulli A, Carobbio A, Gherardi A, Rossi G, Harrison C, Alvarez-Larran A, Elli EM, Kiladjian JJ, Gasior Kabat M, Marin Sanchez A, Palandri F, Andrade-Campos MM, Vannucchi AM, Carreno-Tarragona G, Papadopoulos P, Quiroz Cervantes K, Angeles Focillas M, Fox ML, Sagues Serrano M, Rumi E, Osorio S, Benevolo G, Patriarca A, Navas Elorza B, Garcia-Gutierrez V, Magro Mazo E, Lunghi F, **Bonifacio M**, De Stefano V, Hernandez-Boluda JC, Lopez Abadia E, Angona A, Xicoy Cirici B, Ruggeri M, Koschmieder S, Sobas MA, Cuevas B, Cattaneo D, Daffini R, Bellini M, Curto-Garcia N, Garrote M, Cavalca F, Benajiba L, Bellosillo B, Guglielmelli P, Borsani O, Betti S, Salmoiraghi S, Rambaldi A. Long-term follow-up of recovered MPN patients with COVID-19. *Blood Cancer J.* 2021;11(6):115.

Borghi L, Rosti G, Maggi A, Breccia M, Di Bona E, Iurlo A, La Barba G, Sportoletti P, Albano F, Galimberti S, Rivellini F, Cambrin GR, Capodanno I, Cuneo A, **Bonifacio M**, Sica S, Arcaini L, Capochiani E, Minotto C, Ciceri F, Crugnola M, Di Caprio L, Supekari S, Elena C, Baccarani M, Vegni E. Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy. *Front Oncol.* 2021;11:638689.

Piciocchi A, Messina M, Elia L, Vitale A, Soddu S, Testi AM, Chiaretti S, Mancini M, Albano F, Spadano A, Krampera M, **Bonifacio M**, Cairoli R, Vetro C, Colella F, Ferrara F, Cimino G, Bassan R, Fazi P, Vignetti M. Prognostic impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage acute lymphoblastic leukemia patients treated in GIMEMA clinical trials since 1996. *Am J Hematol.* 2021;96(9):E334-E338.

Barbui T, De Stefano V, Carobbio A, Iurlo A, Alvarez-Larran A, Cuevas B, Ferrer Marin F, Vannucchi AM, Palandri F, Harrison C, Sibai H, Griesshammer M, **Bonifacio M**, Elli EM, Trotti C, Koschmieder S, Carli G, Benevolo G, Ianotto JC, Goel S, Falanga A, Betti S, Cattaneo D, Arellano-Rodrigo E, Mannelli L, Vianelli N, Doyle A, Gupta V, Wille K, Tremblay D, Mascarenhas J. Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients. *Leukemia.* 2021;35(10):2989-2993.

Breccia M, Pregno P, Castagnetti F, **Bonifacio M**, Tiribelli M, Gozzini A, Scortechini AR, Luciano L, Martino B, Stagno F, Caocci G, La Barba G, Pizzuti M, Ciccone G, Saglio G, Specchia G. Eutos long-term survival score discriminates different Sokal score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study. *Leukemia.* 2021;35(6):1814-1816.

Peikert K, Federti E, Matte A, Constantin G, Pietronigro EC, Fabene PF, Defilippi P, Turco E, Del Gallo F, Pucci P, Amoresano A, Illiano A, Cozzolino F, Monti M, Garello F, Terreno E, Alper SL, Glas H, Pelzl L, Akgün K, Ziemssen T, Ordemann R, Lang F, Brunati AM, Tibaldi E, Andolfo I, Iolascon A, Bertini G, Buffelli M, Zancanaro C, Lorenzetto E, Siciliano A, **Bonifacio M**, Danek A, Walker RH, Hermann A, De Franceschi L. Therapeutic targeting of Lyn kinase to treat chorea-acanthocytosis. *Acta Neuropathol Commun.* 2021;9(1):81.

Houshmand M, Garello F, Stefania R, Gaidano V, Cignetti A, Spinelli M, Fava C, Nikougoftar Zarif M, Galimberti S, Pungolino E, Annunziata M, Luciano L, Specchia G, Bocchia M, Binotto G, **Bonifacio M**, Martino B, Pregno P, Stagno F, Iurlo A, Russo S, Aime S, Circosta P, Saglio G. Targeting Chronic Myeloid Leukemia Stem/Progenitor Cells Using Venetoclax-Loaded Immunoliposome. *Cancers (Basel).* 2021;13(6):1311.

Palandri F, Tiribelli M, Breccia M, Bartoletti D, Elli EM, Benevolo G, Martino B, Cavazzini F, Tieghi A, Iurlo A, Abruzzese E, Pugliese N, Binotto G, Caocci G, Auteri G, Cattaneo D, Trawinska MM, Stella R, Scaffidi L, Polverelli N, Micucci G, Masselli E, Crugnola M, Bosi C, Heidel FH, Latagliata R, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Cavo M, Vianelli N, **Bonifacio M**, Palumbo GA*. Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. *Cancer.* 2021;127(15):2657-2665.

*equal co-last authors

Tanasi I, **Bonifacio M**, Pizzolato M, Irene Grifoni F, Sciumè M, Elena C, Benvenuti P, Mannelli F, Parente R, Schena D, Scaffidi L, Bonadonna P, Papayannidis C, Rondoni M, Criscuolo M, Vannucchi AM, Triggiani M, Martinelli G, Krampera M, Zanotti R. Familial occurrence of systemic and cutaneous mastocytosis in an adult multicentre series. *Br J Haematol.* 2021;193(4):845-848.

Latagliata R, Attolico I, Trawinska MM, Capodanno I, Annunziata M, Elena C, Luciano L, Crugnola M, Bergamaschi M, **Bonifacio M**, Barate C, Mauro E, Binotto G, Sgherza N, Aguzzi C, Monteleone B, Sorà F, Caocci G, Luzi D, Marigliò E, Scaffidi L, Cattaneo D, Gozzini A, Di Veroli A, Abruzzese E, Galimberti S, Iurlo A, Specchia G, Breccia M. Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine-kinase inhibitors. *Hematol Oncol.* 2021;39(3):401-408.

Pubblicazioni (continua)

- Malagola M, Iurlo A, Abruzzese E, **Bonifacio M**, Stagno F, Binotto G, D'Adda M, Lunghi M, Crugnola M, Ferrari ML, Lunghi F, Castagnetti F, Rosti G, Lemoli RM, Sancetta R, Coppi MR, Corsetti MT, Rege Cambrin G, Romano A, Tiribelli M, Russo Rossi A, Russo S, Aprile L, Gandolfi L, Farina M, Bernardi S, Polverelli N, Roccaro AM, De Vivo A, Baccarani M, Russo D. Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTIMA study. *Cancer Med*. 2021;10(5):1726-1737.
- Benevolo G, Elli EM, Bartoletti D, Latagliata R, Tiribelli M, Heidel FH, Cavazzini F, **Bonifacio M**, Crugnola M, Binotto G, D'Adda M, Tieghi A, Bergamaschi M, Caocci G, Polverelli N, Bossi E, Auteri G, Carmosino I, Catani L, Cuneo A, Krampera M, Lanza F, Lemoli RM, Vianelli N, Breccia M, Palumbo GA, Cavo M, Palandri F. Impact of comorbidities and body mass index on the outcome of polycythemia vera patients. *Hematol Oncol*. 2021;39(3):409-418.
- Barbui T, De Stefano V, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Ferrari A, Cancelli V, Elli EM, Andrade-Campos MM, Kabat MG, Kiladjian JJ, Palandri F, Benevolo G, Garcia-Gutierrez V, Fox ML, Foncillas MA, Morcillo CM, Rumi E, Osorio S, Papadopoulos P, **Bonifacio M**, Cervantes KSQ, Serrano MS, Carreno-Tarragona G, Sobas MA, Lunghi F, Patriarca A, Elorza BN, Angona A, Mazo EM, Koschmieder S, Carli G, Cuevas B, Hernandez-Boluda JC, Abadia EL, Cirici BX, Guglielmelli P, Garrote M, Cattaneo D, Daffini R, Cavalca F, Bellosillo B, Benajiba L, Curto-Garcia N, Bellini M, Betti S, Harrison C, Rambaldi A, Vannucchi AM. Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. *Blood Cancer J*. 2021;11(2):21.
- Barbui T, Vannucchi AM, De Stefano V, Masciulli A, Carobbio A, Ferrari A, Ghirardi A, Rossi E, Ciceri F, **Bonifacio M**, Iurlo A, Palandri F, Benevolo G, Pane F, Ricco A, Carli G, Caramella M, Rapezzi D, Musolino C, Siragusa S, Rumi E, Patriarca A, Cascavilla N, Mora B, Cacciola E, Mannarelli C, Loscocco GG, Guglielmelli P, Betti S, Lunghi F, Scaffidi L, Bucelli C, Vianelli N, Bellini M, Finazzi MC, Tognoni G, Rambaldi A. Ropeninterferon alfa-2b versus phlebotomy in low-risk patients with polycythemia vera (Low-PV study): a multicentre, randomised phase 2 trial. *Lancet Haematol*. 2021;8(3):e175-e184.
- Barbui T, Vannucchi AM, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Ferrari A, Rossi G, Elli E, Andrade-Campos MM, Kabat MG, Kiladjian JJ, Palandri F, Benevolo G, Garcia-Gutierrez V, Fox ML, Foncillas MA, Morcillo CM, Rumi E, Osorio S, Papadopoulos P, **Bonifacio M**, Cervantes KSQ, Serrano MS, Carreno-Tarragona G, Sobas MA, Lunghi F, Patriarca A, Elorza BN, Angona A, Mazo EM, Koschmieder S, Ruggeri M, Cuevas B, Hernandez-Boluda JC, Abadia EL, Cirici BX, Guglielmelli P, Garrote M, Cattaneo D, Daffini R, Cavalca F, Bellosillo B, Benajiba L, Curto-Garcia N, Bellini M, Betti S, De Stefano V, Harrison C, Rambaldi A. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. *Leukemia*. 2021;35(2):485-493.
- Palandri F, Palumbo GA, Elli EM, Polverelli N, Benevolo G, Martino B, Abruzzese E, Tiribelli M, Tieghi A, Latagliata R, Cavazzini F, Bergamaschi M, Binotto G, Crugnola M, Isidori A, Caocci G, Heidel F, Pugliese N, Bosi C, Bartoletti D, Auteri G, Cattaneo D, Scaffidi L, Trawinska MM, Stella R, Ciantia F, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Iurlo A, Vianelli N, Cavo M, Breccia M, **Bonifacio M**. Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. *Blood Cancer J*. 2021;11(1):4.
- Soverini S, Martelli M, Bavaro L, De Benedittis C, Papayannidis C, Sartor C, Sorà F, Albano F, Galimberti S, Abruzzese E, Annunziata M, Russo S, Stulle M, Imovilli A, **Bonifacio M**, Maino E, Stagno F, Maria Basilico C, Borlenghi E, Fozza C, Mignone F, Minari R, Stella S, Baccarani M, Cavo M, Martinelli G. Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia. *Br J Haematol*. 2021;193(2):271-279.
- Caocci G, Mulas O, Capodanno I, **Bonifacio M**, Annunziata M, Galimberti S, Luciano L, Tiribelli M, Martino B, Castagnetti F, Binotto G, Pugno P, Stagno F, Abruzzese E, Bocchia M, Gozzini A, Albano F, Fozza C, Luzi D, Efficace F, Simula MP, Scaffidi L, Barattè C, De Gregorio F, Stella R, Gugliotta G, Pirillo F, Trawinska MM, Sicuranza A, Cattaneo D, Attolico I, Scalzulli E, Iurlo A, Foà R, Breccia M, La Nasa G. Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib. *Ann Hematol*. 2021 Aug;100(8):2005-2014.
- Soverini S, Martelli M, Bavaro L, De Benedittis C, Sica S, Sorà F, Iurlo A, **Bonifacio M**, Pugno P, Galimberti S, Lunghi F, Albano F, D'Adda M, Crugnola M, Capodanno I, Castagnetti F, Gugliotta G, Papayannidis C, Rosti G, Percepe A, Mignone F, Baccarani M, Martinelli G, Cavo M. BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS. *Leukemia*. 2021;35(7):2102-2107.
- Polverelli N, Elli EM, Abruzzese E, Palumbo GA, Benevolo G, Tiribelli M, **Bonifacio M**, Tieghi A, Caocci G, D'Adda M, Bergamaschi M, Binotto G, Heidel FH, Cavazzini F, Crugnola M, Pugliese N, Bosi C, Isidori A, Bartoletti D, Auteri G, Latagliata R, Gandolfi L, Martino B, Scaffidi L, Cattaneo D, D'Amore F, Trawinska MM, Stella R, Markovic U, Catani L, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Vianelli N, Breccia M, Russo D, Cavo M, Iurlo A, Palandri F. Second primary malignancy in myelofibrosis patients treated with ruxolitinib. *Br J Haematol*. 2021;193(2):356-368.

Pubblicazioni (continua)

- Efficace F, Iurlo A, Patriarca A, Stagno F, Bee PC, Ector G, Capodanno I, Elena C, **Bonifacio M**, Blijlevens NMA, Caocci G, Wan C, Abruzzese E, Breccia M, Cottone F, Okumura I, Oerlemans S, Cascavilla N, Albano F, Kota V, Sztankay M, Miggiano MC, Saussele S, Di Renzo N, Sorà F, Castagnetti F, Baccarani M, Vignetti M, Rosti G. Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia. *Leuk Lymphoma*. 2021;62(3):669-678.
- Foà R, Bassan R, Vitale A, Elia L, Piciocchi A, Puzzolo MC, Canichella M, Viero P, Ferrara F, Lunghi M, Fabbiano F, **Bonifacio M**, Fracchiolla N, Di Bartolomeo P, Mancino A, De Propriis MS, Vignetti M, Guarini A, Rambaldi A, Chiaretti S; GIMEMA Investigators. Dasatinib-blinatumomab for Ph-positive Acute Lymphoblastic Leukemia in Adults. *N Engl J Med*. 2020;383(17):1613-1623.
- Takam Kamga P, Dal Collo G, Cassaro A, Bazzoni R, Delfino P, Adamo A, Bonato A, Carbone C, Tanasi I, **Bonifacio M**, Krampera M. Small molecule inhibitors of microenvironmental Wnt/ β -catenin enhance the chemosensitivity of acute myeloid leukemia. *Cancers (Basel)*. 2020;12(9):2696.
- Candoni A, Lazzarotto D, Ferrara F, Curti A, Lussana F, Papayannidis C, Del Principe ML, **Bonifacio M**, Mosna F, Delia M, Minetto P, Gottardi M, Fracchiolla N, Mancini V, Forghieri F, Zappasodi P, Cerrano M, Vitale A, Audisio E, Trappolini S, Romani C, Defina M, Imbergamo S, Ciccone N, Santoro L, Cambò B, Iaccarino S, Dargenio M, Aprile L, Chiaretti S, Fanin R, Pizzolo G, Foà R. Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma. A Campus ALL study. *Am J Hematol*. 2020;95(12):1466-1472.
- Gökbuget N, Zugmaier G, Dombret H, Stein A, **Bonifacio M**, Graux C, Faul C, Brüggemann M, Taylor K, Mergen N, Reichle A, Horst HA, Havelange V, Topp MS, Bargou RC. Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia. *Leuk Lymphoma*. 2020;61(11):2665-2673.
- Mulas O, Caocci G, Annunziata M, Martino B, Luciano L, Castagnetti F, Pregno P, Galimberti S, Albano F, Orlandi EM, Sgherza N, Iurlo A, **Bonifacio M**, Binotto G, Gozzini A, Bocchia M, Abruzzese E, Fozza C, Simula MP, De Gregorio F, Gugliotta G, Pirillo F, Barattè C, Attolico I, Elena C, Cattaneo D, Scaffidi L, Sicuranza A, Trawinska MM, Scalzulli E, Foà R, Breccia M, La Nasa G. Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib. *Hematol Oncol*. 2020;38(4):607-610.
- Annunziata M, **Bonifacio M**, Breccia M, Castagnetti F, Gozzini A, Iurlo A, Pregno P, Stagno F, Specchia G. Current strategies and future directions to achieve deep molecular response and treatment-free remission in chronic myeloid leukemia. *Front Oncol*. 2020;10:883. [Review]
- Breccia M, Abruzzese E, Bocchia M, **Bonifacio M**, Castagnetti F, Fava C, Galimberti S, Gozzini A, Gugliotta G, Iurlo A, Latagliata R, Luciano L, Pregno P, Rege-Cambrin G, Rosti G, Stagno F, Tiribelli M, Foà R, Saglio G; Campus CML working group. Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A Campus CML survey. *Leukemia*. 2020;34(8):2260-2261.
- Caocci G, Mulas O, Capodanno I, Abruzzese E, Iurlo A, Luciano L, Albano F, Annunziata M, Tiribelli M, **Bonifacio M**, Galimberti S, Castagnetti F, Sgherza N, Stagno F, Gozzini A, Orlandi EM, Luzi D, Binotto G, Pregno P, Fozza C, Efficace F, Simula MP, Trawinska MM, Cattaneo D, De Gregorio F, Attolico I, Stella R, Scaffidi L, Barattè C, Gugliotta G, Scalzulli E, Elena C, Pirillo F, Foà R, Breccia M, La Nasa G. Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study. *Blood Cancer J*. 2020;10(6):66.
- Mulas O, Caocci G, Stagno F, **Bonifacio M**, Annunziata M, Luciano L, Orlandi EM, Abruzzese E, Sgherza N, Martino B, Albano F, Galimberti S, Pregno P, Bocchia M, Castagnetti F, Tiribelli M, Binotto G, Gozzini A, Capodanno I, Fozza C, Luzi D, Efficace F, Simula MP, Scaffidi L, De Gregorio F, Elena C, Trawinska MM, Cattaneo D, Attolico I, Barattè C, Pirillo F, Sicuranza A, Gugliotta G, Stella R, Scalzulli E, Iurlo A, Foà R, Breccia M, La Nasa G. Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors. *Ann Hematol*. 2020;99(7):1525-1530.
- Foà R, **Bonifacio M**, Chiaretti S, Curti A, Candoni A, Fava C, Ciccone M, Pizzolo G, Ferrara F. Philadelphia-positive acute lymphoblastic leukaemia (ALL) in Italy during the COVID-19 pandemic: a Campus ALL study. *Br J Haematol*. 2020;190(1):e3-e5.
- Cesini L, Frieri C, Barattè C, Sorà F, **Bonifacio M**, Cerrano M, Cagnetta A, Elena C, Aprile L, Sgherza N, Trawinska M, Gozzini A, Capodanno I, Crugnola M, Carmosino I, Scalzulli E, Ricci F, Bocchia M, Bergamaschi M, Aguzzi C, Sica S, Galimberti S, Breccia M, Luciano L, Latagliata R. Erythropoietin treatment in chronic phase chronic myeloid leukemia patients treated with frontline imatinib who developed late anemia. *Eur J Haematol*. 2020;105(3):286-291.

Pubblicazioni (continua)

- Palandri F, Breccia M, Tiribelli M, **Bonifacio M**, Benevolo G, Iurlo A, Elli EM, Binotto G, Tieghi A, Polverelli N, Martino B, Abruzzese E, Bergamaschi M, Heidel FH, Cavazzini F, Crugnola M, Bosi C, Isidori A, Auteri G, Forte D, Latagliata R, Griguolo D, Cattaneo D, Trawinska M, Bartoletti D, Krampera M, Semenzato G, Lemoli RM, Cuneo A, Di Raimondo F, Vianelli N, Cavo M, Palumbo GA. Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: real-world data. *Hematol Oncol*. 2020;38(3):372-380.
- Tomasello L, Vezzalini M, Boni C, **Bonifacio M**, Scaffidi L, Yassin M, Al-Dewik N, Takam Kamga P, Krampera M, Sorio C. Regulative loop between β -catenin and Protein Tyrosin Receptor Type γ in Chronic Myeloid Leukemia. *Int J Mol Sci*. 2020;21(7):2298.
- Trizuljak J, Sperr WR, Nekvindová L, Elberink HO, Gleixner KV, Gorska A, Lange M, Hartmann K, Illerhaus A, **Bonifacio M**, Perkins C, Elena C, Malcovati L, Fortina AB, Shoumariyeh K, Jawhar M, Zanotti R, Bonadonna P, Caroppo F, Zink A, Triggiani M, Parente R, von Bubnoff N, Yavuz AS, Häggglund H, Mattsson M, Panse J, Jäkel N, Kilbertus A, Hermine O, Arock M, Fuchs D, Sabato V, Brockow K, Bretterklieber A, Niedoszytko M, van Anrooij B, Reiter A, Gotlib J, Kluin-Nelemans HC, Mayer J, Doubek M, Valent P. Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification. *Allergy*. 2020;75(8):1927-1938.
- Del Principe ML, Buzzatti E, Piciocchi A, Forghieri F, **Bonifacio M**, Lessi F, Imbergamo S, Orciuolo E, Rossi G, Fracchiolla N, Trappolini S, Neri B, Sarlo C, Zappasodi P, Dargenio M, Cefalo M, Irno-Consalvo MA, Conti C, Paterno G, De Angelis G, Sciumè M, Della Starza I, Venditti A, Foà R, Guarini AR. Clinical significance of occult central nervous system disease in adult acute lymphoblastic leukemia. A multicenter report from the Campus ALL network. *Haematologica*. 2019 Dec 26 [online ahead of print]
- Soverini S, Bavaro L, De Benedittis C, Martelli M, Iurlo A, Orofino N, Sica S, Sorà F, Lunghi F, Ciceri F, Galimberti S, Baratè C, **Bonifacio M**, Scaffidi L, Castagnetti F, Gugliotta G, Albano F, Russo Rossi AV, Stagno F, di Raimondo F, D'Adda M, di Bona E, Abruzzese E, Binotto G, Sancetta R, Salvucci M, Capodanno I, Girasoli M, Coluzzi S, Attolico I, Musolino C, Calistri E, Annunziata M, Bocchia M, Stella S, Serra A, Errichiello S, Saglio G, Pane F, Vigneri P, Mignone F, Laginestra MA, Pileri SA, Percesepe A, Tenti E, Rosti G, Baccarani M, Cavo M, Martinelli G. Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. *Blood*. 2020;135(8):534-541.
- Baccarani M, Abruzzese E, Accurso V, Albano F, Annunziata M, Barulli S, Beltrami G, Bergamaschi M, Binotto G, Bocchia M, Caocci G, Capodanno I, Cavazzini F, Cedrone M, Cerrano M, Crugnola M, D'Adda M, Elena C, Fava C, Fazi P, Fozza C, Galimberti S, Gai V, Gozzini A, Gugliotta G, Iurlo A, La Barba G, Levato L, Lucchesi A, Luciano L, Lunghi F, Lunghi M, Malagola M, Marasca R, Martino B, Melpignano A, Miggiano MC, Montefusco E, Musolino C, Palmieri F, Pregno P, Rapezzi D, Rege-Cambrin G, Rupoli S, Salvucci M, Sancetta R, Sica S, Spadano R, Stagno F, Tiribelli M, Tomassetti S, Trabacchi E, **Bonifacio M**, Breccia M, Castagnetti F, Pane F, Russo D, Saglio G, Soverini S, Vigneri P, Rosti G. Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. *Blood Adv*. 2019;3(24):4280-4290.
- De Stefano V, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, Rossi E, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Finazzi G, **Bonifacio M**, Scaffidi L, Patriarca A, Rumi E, Casetti IC, Stephenson C, Guglielmelli P, Elli EM, Palova M, Rapezzi D, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Isfort S, Marchetti M, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Rambaldi A, Barbui T. Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study. *Blood*. 2020;135(5):381-386.
- Palandri F, Breccia M, **Bonifacio M**, Polverelli N, Elli EM, Benevolo G, Tiribelli M, Abruzzese E, Iurlo A, Heidel FH, Bergamaschi M, Tieghi A, Crugnola M, Cavazzini F, Binotto G, Isidori A, Sgherza N, Bosi C, Martino B, Latagliata R, Auteri G, Scaffidi L, Griguolo D, Trawinska M, Cattaneo D, Catani L, Krampera M, Lemoli RM, Cuneo A, Semenzato G, Foà R, Di Raimondo F, Bartoletti D, Cavo M, Palumbo GA, Vianelli N. Life after ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. *Cancer*. 2020;126(6):1243-1252.
- Breccia M, Baratè C, Benevolo G, **Bonifacio M**, Elli EM, Guglielmelli P, Maffioli M, Malato A, Mendicino F, Palumbo GA, Pugliese N, Rossi E, Rumi E, Sant'Antonio E, Ricco A, Tiribelli M, Palandri F. Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-world practice. *Ann Hematol*. 2020;99(1):65-72.
- Takam Kamga P, Dal Collo G, Resci F, Bazzoni R, Mercuri A, Quaglia FM, Tanasi I, Delfino P, Visco C, **Bonifacio M**, Krampera M. Notch signaling molecules as prognostic biomarkers for acute myeloid leukemia. *Cancers (Basel)*. 2019;11(12):1958.
- Marchetti M, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, Rossi E, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Finazzi G, **Bonifacio M**, Scaffidi L, Patriarca A, Rumi E, Casetti IC, Stephenson C, Guglielmelli P, Elli EM, Palova M, Rapezzi D, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Isfort S, Pane F, De Stefano V, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Rambaldi A, Barbui T. Second cancers in MPN: survival analysis from an international study. *Am J Hematol*. 2020;95(3):295-301.

Pubblicazioni (continua)

- Soverini S, Abruzzese E, Bocchia M, **Bonifacio M**, Galimberti S, Gozzini A, Iurlo A, Luciano L, Pregno P, Rosti G, Saglio G, Stagno F, Tiribelli M, Vigneri P, Barosi G, Breccia M. Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper. *J Hematol Oncol*. 2019;12(1):131.
- Caocci G, Mulas O, Annunziata M, Luciano L, Abruzzese E, **Bonifacio M**, Orlandi EM, Albano F, Galimberti S, Iurlo A, Pregno P, Sgherza N, Martino B, Binotto G, Castagnetti F, Gozzini A, Bocchia M, Fozza C, Stagno F, Simula MP, De Gregorio F, Trawinska MM, Scaffidi L, Elena C, Attolico I, Barate C, Cattaneo D, Pirillo F, Gugliotta G, Sicuranza A, Molica M, La Nasa G, Foà R, Breccia M. Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- or third-generation tyrosin kinase inhibitors. *Int J Cardiol*. 2020;301:163-166.
- Bonifacio M**, Stagno F, Scaffidi L, Krampera M, Di Raimondo F. Management of chronic myeloid leukemia in advanced phase. *Front Oncol*. 2019;9:1132. [Review]
- Sperr WR, Kundi M, Alvarez-Twose I, van Anrooij B, Oude Elberink JNG, Gorska A, Niekisz-Kordecka M, Gleixner KV, Hadzijusufovic E, Zanotti R, Bonadonna P, **Bonifacio M**, Perkins C, Illerhaus A, Elena C, Merante S, Shoumariyeh K, von Bubnoff N, Parente R, Jawhar M, Belloni Fortina A, Caroppo F, Brockow K, Zink A, Fuchs D, Kilbertus AJ, Yavuz AS, Doubek M, Hägglund H, Panse J, Sabato V, Bretterklieber A, Niederwieser D, Breynaert C, Hartmann K, Triggiani M, Niekisz-Kordecka B, Reiter A, Orfao A, Hermine O, Gottlieb J, Arock M, Kluin-Nelemans HC, Valent P. International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. *Lancet Haematol*. 2019;6(12):e638-e649.
- Tiribelli M, Palandri F, Sant'Antonio E, Breccia M, **Bonifacio M**. The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review. *Bone Marrow Transplant*. 2020;55(4):708-716. [Review]
- Tiribelli M, Abruzzese E, Capodanno I, Sorà F, Trabacchi E, Iurlo A, Luciano L, Binotto G, **Bonifacio M**, Annunziata M, Crugnola M, Fanin R. Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy. *Ann Hematol*. 2019;98(11):2609-2611.
- Mimiola E, Bomben R, De Matteis G, Perbellini O, Guglielmelli P, **Bonifacio M**, Parisi A, Gattei V, Zamò A, Mannelli F, García Montero AC, Zanotti R. Systemic mastocytosis associated with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: report of three cases. *Hematol Oncol*. 2019;37(5):628-633.
- Efficace F, Stagno F, Iurlo A, Breccia M, Cottone F, **Bonifacio M**, Abruzzese E, Castagnetti F, Caocci G, Crugnola M, Capodanno I, Martino B, Tiribelli M, Patriarca A, Gozzini A, Pregno P, Saussele S, Cascavilla N, Fozza C, Bergamaschi M, Binotto G, Vignetti M, Rosti G. Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy. *Leukemia*. 2020;34(2):488-498.
- Sant'Antonio E, **Bonifacio M**, Breccia M, Rumi E. A journey through infectious risk associated with ruxolitinib. *Br J Haematol*. 2019;187(3):286-295. [Review]
- Tanasi I, Ba I, Sirvent N, Braun T, Cuccuini W, Ballerini P, Duployez N, Tanguy-Schmidt A, Tamburini J, Maury S, Doré E, Himberlin C, Duclos C, Chevallier P, Rousselot P, **Bonifacio M**, Cavé H, Baruchel A, Dombret H, Soulier J, Landman-Parker J, Boissel N, Clappier E. Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements. *Blood*. 2019;134(16):1351-1355.
- Crugnola M, Castagnetti F, Breccia M, Ferrero D, Trawinska MM, Abruzzese E, Annunziata M, Stagno F, Tiribelli M, Binotto G, **Bonifacio M**, Fava C, Iurlo A, Bucelli C, Mansueto G, Gozzini A, Falzetti F, Montefusco E, Crisà E, Gugliotta G, Russo S, Cedrone M, RussoRossi A, Pregno P, Isidori A, Mauro E, Atelda R, Giglio G, Celesti F, Sorà F, Storti S, D'Addosio A, Galimberti S, Orlandi E, Calistri E, Bocchia M, Cavazzini F, Rege Cambrin G, Orofino N, Luciano L, Sgherza N, Rosti G, Latagliata R, Capodanno I. Outcome of very elderly chronic myeloid leukemia patients treated with imatinib frontline. *Ann Hematol*. 2019;98(10):2329-2338.
- Bonifacio M**, Montemezzi R, Parisi A, De Matteis G, Bertorelle R, Scaffidi L, Candiotti C, Lippi G, Zamò A, Chilosi M, Pizzolo G, Scarpa A, Krampera M. CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia patients. *Ann Hematol*. 2019;98(10):2339-2346.
- Bernardi S, **Bonifacio M**, Iurlo A, Zanaglio C, Tiribelli M, Binotto G, Abruzzese E, Russo D. "Variant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the European Against Cancer qPCR assay." Is dPCR the key? *Eur J Haematol*. 2019;103(3):272-273.
- Breccia M, Luciano L, Pugliese N, Rossi E, Tiribelli M, Scalzulli E, **Bonifacio M**, Martino B, Latagliata R, Benevolo G, Caocci G, Binotto G, Martinelli V, Cavo M, Pane F, De Stefano V, Foà R, Palandri F. Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis. *Ann Hematol*. 2019;98(8):1933-1936.

Pubblicazioni (continua)

- Barbui T, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, De Stefano V, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Delaini F, **Bonifacio M**, Scaffidi L, Patriarca A, Rumi E, Casetti IC, Stephenson C, Guglielmelli P, Elli EM, Palova M, Bertolotti L, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Marchetti M, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Finazzi G. Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. *Leukemia*. 2019;33(8):1996-2005.
- Caocci G, Mulas O, Abruzzese E, Iurlo A, Annunziata M, Orlandi EM, Galimberti S, Binotto G, Sgherza N, Luciano L, Martino B, Russo Rossi A, **Bonifacio M**, Fozza C, Trawinska MM, Cattaneo D, Elena C, Barate C, De Gregorio F, Molica M, La Nasa G, Foà R, Breccia M. Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice. *Ann Hematol*. 2019;98(8):1885-1890.
- Caocci G, Mulas O, **Bonifacio M**, Abruzzese E, Galimberti S, Orlandi EM, Iurlo A, Annunziata M, Luciano L, Castagnetti F, Gozzini A, Stagno F, Binotto G, Pregno P, Albano F, Martino B, Fozza C, Scaffidi L, Trawinska MM, Barate C, Elena C, Cattaneo D, Scalzulli E, La Nasa G, Foà R, Breccia M. Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention. *Int J Cardiol*. 2019;288:124-127.
- Palandri F, Palumbo GA, Abruzzese E, Iurlo A, Polverelli N, Elli E, **Bonifacio M**, Bergamaschi M, Martino B, Tiribelli M, Benevolo G, Tieghi A, Sgherza N, Isidori A, Binotto G, Crugnola M, Heidel F, Cavazzini F, Bosi C, Auteri G, Cattaneo D, Foà R, Lemoli RM, Cuneo A, Krampera M, Bartoletti D, Cavo M, Vianelli N, Breccia M, Latagliata R. Impact of 2016 WHO diagnosis of early and over primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. *Hematol Oncol*. 2019;37(4):418-423.
- Bernardi S, Malagola M, Zanaglio C, Polverelli N, Dereli Eke E, D'Adda M, Farina M, Bucelli C, Scaffidi L, Toffoletti E, Deambrogi C, Stagno F, Bergamaschi M, Franceschini L, Abruzzese E, Divona MD, Gobbi M, Di Raimondo F, Gaidano G, Tiribelli M, **Bonifacio M**, Cattaneo C, Iurlo A, Russo D. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation. *Cancer Med*. 2019;8(5):2041-2055.
- Caocci G, Mulas O, Abruzzese E, Luciano L, Iurlo A, Attolico I, Castagnetti F, Galimberti S, Sgherza N, **Bonifacio M**, Annunziata M, Gozzini A, Orlandi EM, Stagno F, Binotto G, Pregno P, Fozza C, Trawinska MM, De Gregorio F, Cattaneo D, Albano F, Gugliotta G, Barate C, Scaffidi L, Elena C, Pirillo F, Scalzulli E, La Nasa G, Foà R, Breccia M. Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. *Hematol Oncol*. 2019;37(3):296-302.
- Borghi L, Galimberti S, Barate C, **Bonifacio M**, Capochiani E, Cuneo A, Falzetti F, Iurlo A, Lunghi F, Minotto C, Orlandi EM, Rege-Cambrin G, Sica S, Supekar S, Haenig J, Vegni E. Chronic Myeloid Leukemia Patient's Voice About the Experience of Treatment-Free Remission Failure: Results From the Italian Sub-Study of ENESTPath Exploring the Emotional Experience of Patients During Different Phases of a Clinical Trial. *Front Psychol*. 2019;10:329.
- Takam Kamga P, Dal Collo G, Midolo M, Adamo A, Delfino P, Mercuri A, Cesaro S, Mimiola E, **Bonifacio M**, Andreini A, Chilosi M, Krampera M. Inhibition of Notch signaling enhances chemosensitivity in B cell precursor acute lymphoblastic leukemia. *Cancer Res*. 2019;79(3):639-649.
- Palandri F, Palumbo GA, Iurlo A, Polverelli N, Benevolo G, Breccia M, Abruzzese E, Tiribelli M, **Bonifacio M**, Tieghi A, Isidori A, Martino B, Sgherza N, D'Adda M, Bergamaschi M, Crugnola M, Cavazzini F, Bosi C, Binotto G, Auteri G, Latagliata R, Ibatici A, Scaffidi L, Penna D, Cattaneo D, Soci F, Trawinska M, Russo D, Cuneo A, Semenzato G, Di Raimondo F, Aversa F, Lemoli RM, Fanin R, Reggiani MLB, Bartoletti D, Cavo M, Catani L, Vianelli N. Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study. *Semin Hematol*. 2018;55(4):248-255.
- Breccia M, Bartoletti D, **Bonifacio M**, Palumbo GA, Polverelli N, Abruzzese E, Bergamaschi M, Tieghi A, Tiribelli M, Iurlo A, Cavazzini F, Sgherza N, Binotto G, Isidori A, D'Adda M, Crugnola M, Bosi C, Heidel F, Molica M, Scaffidi L, Cattaneo D, Latagliata R, Auteri G, Lemoli RM, Fanin R, Russo D, Aversa F, Cuneo A, Semenzato G, Catani L, Cavo M, Vianelli N, Foà R, Palandri F. Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. *Ann Hematol*. 2019;98(4):889-896.
- Valent P, Oude Elberink JNG, Gorska A, Lange M, Zanotti R, van Anrooij B, **Bonifacio M**, Bonadonna P, Gleixner KV, Hadzijusufovic E, Perkins C, Hartmann K, Illerhaus A, Merante S, Elena C, Shoumariyeh K, von Bubnoff N, Parente R, Triggiani M, Schwaab J, Jawhar M, Caroppo F, Fortina AB, Brockow K, David Fuchs, Greul R, Yavuz AS, Doubek M, Mattsson M, Hagglund H, Panse J, Sabato V, Aberer E, Al-Ali HK, Morren MA, Varkonyi J, Zink A, Niekiszko M, Niederwieser D, Malcovati L, Reiter A, Kennedy V, Gotlib J, Lortholary O, Hermine O, Arock M, Kluin-Nelemans H, Sperr WR; Study Group of the European Competence Network on Mastocytosis (ECNM). The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. *J Allergy Clin Immunol Pract*. 2019;7(1):81-87.

Pubblicazioni (continua)

Palandri F, Palumbo GA, **Bonifacio M**, Breccia M, Latagliata R, Martino B, Polverelli N, Abruzzese E, Tiribelli M, Nicolosi M, Bergamaschi M, Tieghi A, Iurlo A, Sgherza N, Cavazzini F, Isidori A, Binotto G, Ibatici A, Crugnola M, Heidel F, Bosi C, Bartoletti D, Auteri G, Catani L, Cuneo A, Aversa F, Semenzato G, Cavo M, Vianelli N, Benevolo G. Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. *Leuk Res*. 2018;74:86-88.

Bonifacio M, Scaffidi L, Binotto G, Miggiano MC, Danini M, Minotto C, Griguolo D, Marin L, Frison L, D'Amore F, Basso M, Sartori R, Tinelli M, Stulle M, Fortuna S, Bonalumi A, Bertoldo G, De Biasi E, Ruggeri M, Semenzato G, Fanin R, Pizzolo G, Krampera M, Tiribelli M. Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy. *Leuk Res*. 2018;74:75-79.

Palandri F, Catani L, **Bonifacio M**, Benevolo G, Heidel F, Palumbo GA, Crugnola M, Abruzzese E, Bartoletti D, Polverelli N, Bergamaschi M, Tiribelli M, Iurlo A, Breccia M, Cavazzini F, Tieghi A, Binotto G, Isidori A, Martino B, D'Adda M, Bosi C, Sabbatini E, Vitolo U, Aversa F, Ibatici A, Lemoli RM, Sgherza N, Cuneo A, Martinelli G, Semenzato G, Cavo M, Vianelli N, Sapienza MR, Latagliata R. Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients. *Br J Haematol* 2018;183(1):35-46.

Orsolini G, Viapiana O, Rossini M, **Bonifacio M**, Zanotti R. Bone disease in mastocytosis. *Immunol Allergy Clin North Am*. 2018;38(3):443-454.

Kamga PT, Dal Collo G, Bassi G, Midolo M, Delledonne M, Chilosi M, **Bonifacio M**, Krampera M. Characterization of a new B-ALL cell line with constitutional defects of the Notch signaling pathway. *Oncotarget* 2018;9(26):18341-18350.

Breccia M, Abruzzese E, Castagnetti F, **Bonifacio M**, Gangemi D, Sorà F, Iurlo A, Luciano L, Gozzini A, Gentile M, Bocchia M, Luzi D, Maggi A, Sgherza N, Isidori A, Crugnola M, Pregno P, Scortechini AR, Capodanno I, Pizzuti M, Foà R. Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. *Ann Hematol* 2018;97(9):1577-1580.

Caocci G, Mulas O, Annunziata M, Luciano L, **Bonifacio M**, Orlandi EM, Pregno P, Galimberti S, Russo Rossi A, Abruzzese E, Iurlo A, Martino B, Sgherza N, Binotto G, Castagnetti F, Gozzini A, Fozza C, Bocchia M, Sicuranza A, Stagno F, Efficace F, Usala E, De Gregorio F, Scaffidi L, Elena C, Pirillo F, Barate C, Trawinska MM, Cattaneo D, Labate C, Gugliotta G, Molica M, Specchia G, La Nasa G, Foà R, Breccia M. Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: identification of risk factors and the role of prophylaxis. *Am J Hematol* 2018;93(7):e159-e161.

Polverelli N, Palumbo GA, Binotto G, Abruzzese E, Benevolo G, Bergamaschi M, Tieghi A, **Bonifacio M**, Breccia M, Catani L, Tiribelli M, D'Adda M, Sgherza N, Isidori A, Cavazzini F, Martino B, Latagliata R, Crugnola M, Heidel F, Bosi C, Ibatici A, Soci F, Penna D, Scaffidi L, Aversa F, Lemoli RM, Vitolo U, Cuneo A, Russo D, Cavo M, Vianelli N, Palandri F. Epidemiology, outcome and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: a multicenter study on 446 patients. *Hematol Oncol* 2018 Apr 6 doi: 10.1002/hon.2509. [Epub ahead of print]

Tiribelli M*, **Bonifacio M***, Binotto G, Iurlo A, Cibien F, Maino E, Guella A, Festini G, Minotto C, De Biasi E, De Marchi F, Scaffidi L, Frison L, Bucelli C, Medeot M, Calistri E, Sancetta R, Stulle M, Orofino N, Krampera M, Gherlinzoni F, Semenzato G, Pizzolo G, Ambrosetti A, Fanin R. Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients. *Oncotarget* 2018;9(18):14219-14227.

* co-first authors

De Stefano V, Carobbio A, Di Lazzaro V, Guglielmelli P, Iurlo A, Finazzi MC, Rumi E, Cervantes F, Elli EM, Randi ML, Griesshammer M, Palandri F, **Bonifacio M**, Hernandez-Boluda JC, Cacciola R, Miroslava P, Carli G, Beggiato E, Ellis MH, Musolino C, Gaidano G, Rapezzi D, Tieghi A, Lunghi F, Loscocco GG, Cattaneo D, Cortelezzi A, Betti S, Rossi E, Finazzi G, Corsi B, Cazzola M, Bellini M, Arellano-Rodrigo E, Bertozzi I, Sadjadian P, Vianelli N, Scaffidi L, Gomez M, Cacciola E, Vannucchi AM, Barbui T. Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. *Blood Cancer J* 2018;8(3):25.

Palandri F, Benevolo G, Iurlo A, Abruzzese E, Carella AM, Paoli C, Palumbo GA, **Bonifacio M**, Cilloni D, Andriani A, Guarini A, Turri D, Elli EM, Falcone A, Anaclerio B, Musto P, Di Renzo N, Tiribelli M, Zambello R, Spinosa C, Ricco A, Raucio L, Martino B, Annunziata M, Pascale S, Liberati AM, La Nasa G, Maffioli M, Breccia M, Pugliese N, Betti S, Giglio G, Cappuccio A, Reale L. Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine – results from the Italian 'Back to Life' project. *Qual Life Res* 2018;27(6):1545-1554.

Breccia M, Palandri F, Luciano L, Benevolo G, **Bonifacio M**, Caocci G, Castagnetti F, Palumbo GA, Iurlo A, Landi F. Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitors treatment. *Ann Hematol* 2018;97(5):745-754.

Pubblicazioni (continua)

- Gökbuget N, Dombret H, **Bonifacio M**, Reichle A, Graux C, Faul C, Diedrich H, Topp MS, Brüggemann M, Horst HA, Havelange V, Stieglmaier J, Wessels H, Haddad V, Benjamin JE, Zugmaier G, Nagorsen D, Bargou RC. Blinatumomab for minimal residual disease in adults with B-precursor acute lymphoblastic leukemia. *Blood* 2018;131(14):1522-1531.
- Bonadonna P, Zanotti R, Pagani M, **Bonifacio M**, Scaffidi L, Olivieri E, Franchini M, Reccardini F, Costantino MT, Roncallo C, Mauro M, Boni E, Rizzini FL, Bilò MB, Marcarelli AR, Passalacqua G. Anaphylactic reactions after discontinuation of hymenoptera venom immunotherapy: a clonal mast cell disorder should be suspected. *J Allergy Clin Immunol Pract* 2018;6(4):1368-1372.
- Bonifacio M**, Zanotti R, Guardalben E, Mimiola E, Scognamiglio F, Perbellini O, De Matteis G, Escribano L, Bonadonna P, Grigolato D, Bissoli S, Parisi A, Zamò A, Ambrosetti A, Rossini M. Multiple large osteolytic lesions in a patient with systemic mastocytosis: a challenging diagnosis. *Clin Case Rep* 2017;5(12):1988-1991.
- Palandri F, Palumbo GA, **Bonifacio M**, Tiribelli M, Benevolo G, Martino B, Abruzzese E, D'Adda M, Polverelli N, Bergamaschi M, Tieghi A, Cavazzini F, Ibatici A, Crugnola M, Bosi C, Latagliata R, Di Veroli A, Scaffidi L, de Marchi F, Cerqui E, Anaclerio B, De Matteis G, Spinsanti M, Sabbatini E, Catani L, Aversa F, Di Raimondo F, Vitolo U, Lemoli RM, Fanin R, Merli F, Russo D, Cuneo A, Bacchi Reggiani ML, Cavo M, Vianelli N, Breccia M. Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. *Oncotarget* 2017;8(45):79073-79086.
- Iurlo A, Galimberti S, Abruzzese E, Annunziata M, **Bonifacio M**, Latagliata R, Pregno P, Ferrero D, Sorà F, Orlandi EM, Fava C, Cattaneo D, Bucelli C, Binotto G, Pungolino E, Tiribelli M, Gozzini A, Gugliotta G, Castagnetti F, Stagno F, Rege-Cambrin G, Martino B, Luciano L, Breccia M, Sica S, Bocchia M, Pane F, Saglio G, Rosti G, Specchia G, Cortelezzi A, Baccarani M. Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. *Ann Hematol* 2018;97(1):95-100.
- Tiribelli M, Binotto G, **Bonifacio M**. The significance of early warning in chronic myeloid leukemia. *Expert Rev Hematol* 2018;11(4):265-266.
- Gugliotta G, Castagnetti F, Breccia M, Albano F, Iurlo A, Intermesoli T, Abruzzese E, Levato L, D'Adda M, Pregno P, Cavazzini F, Stagno F, Martino B, La Barba G, Sorà F, Tiribelli M, Bigazzi C, Binotto G, **Bonifacio M**, Caracciolo C, Soverini S, Foà R, Cavo M, Martinelli G, Pane F, Saglio G, Baccarani M, Rosti G. Incidence of secondary primary malignancies and related mortality in imatinib-treated chronic myeloid leukemia patients. *Haematologica* 2017;102(9):1530-1536.
- Palandri F, Tiribelli M, Benevolo G, Tieghi A, Cavazzini F, Breccia M, Bergamaschi M, Sgherza N, Polverelli N, Crugnola M, Isidori A, Binotto G, Heidele FH, Buccisano F, Martino B, Latagliata R, Spinsanti M, Kallenberg L, Palumbo GA, Abruzzese E, Scaffidi L, Cuneo A, Cavo M, Vianelli N, **Bonifacio M**. Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: results from an independent study. *Hematol Oncol* 2018;36(1):285-290.
- Castagnetti F, Gugliotta G, Breccia M, Iurlo A, Levato L, Albano F, Vigneri P, Abruzzese E, Rossi G, Rupoli S, Cavazzini F, Martino B, Orlandi E, Pregno P, Annunziata M, Usala E, Tiribelli M, Sica S, **Bonifacio M**, Fava C, Gherlinzoni F, Bocchia M, Soverini S, Boichicchio MT, Cavo M, Giovanni M, Saglio G, Pane F, Baccarani M, Rosti G. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib. *Am J Hematol* 2017;92(8):797-805.
- Perricone M, Palandri F, Ottaviani E, Angelini M, Bagli L, Bellesia E, Donati M, Gemmati D, Zucchini P, Mancini S, Marchica V, Trubini S, De Matteis G, Di Zaccaro S, Favarato M, Fioroni A, Bolzonella C, Maccari G, Navaglia F, Gatti D, Toffolatti L, Orlandi L, Laloux V, Manfrini M, Galieni P, Giannini B, Tieghi A, Barulli S, Serino ML, Maccaferri M, Scortechini AR, Giuliani N, Vallisa D, **Bonifacio M**, Accorsi P, Salbe C, Fazio V, Gusella M, Toffoletti E, Salvucci M, Svaldi M, Gherlinzoni F, Cassavia F, Orsini F, Martinelli G. Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: a study involving a consortium of 19 Italian laboratories. *Oncotarget* 2017;8(20):32608-32617.
- Bonadonna P, **Bonifacio M**, Zanotti R. Mast Cell Disorders in Drug Hypersensitivity. *Curr Pharm Des* 2016;22(45):6862-6869.
- Artuso A, Caimmi C, Tripi G, Viapiana O, **Bonifacio M**, Idolazzi L, Gavioli I, Gatti D, Zanotti R, Rossini M. Longitudinal evaluation of bone mineral density and bone metabolism markers in patients with indolent systemic mastocytosis without osteoporosis. *Calcif Tissue Int* 2017;100(1):40-46.
- Latagliata R, Stagno F, Annunziata M, Abruzzese E, Iurlo A, Guarini A, Fava C, Gozzini A, **Bonifacio M**, Sorà F, Leonetti Crescenzi S, Bocchia M, Crugnola M, Castagnetti F, Capodanno I, Galimberti S, Feo C, Porrini R, Pregno P, Rizzo M, Antolino A, Mauro E, Sgherza N, Luciano L, Tiribelli M, Russo Rossi A, Trawinska M, Vigneri P, Breccia M, Rosti G, Alimena G. Frontline dasatinib treatment in a "real-life" cohort of patients older than 65 years with chronic myeloid leukemia. *Neoplasia* 2016;18(9):536-540.

Pubblicazioni (continua)

Iurlo A, Nobili A, Latagliata R, Bucelli C, Castagnetti F, Breccia M, Abruzzese E, Cattaneo D, Fava C, Ferrero D, Gozzini A, **Bonifacio M**, Tiribelli M, Pregno P, Stagno F, Vigneri P, Annunziata M, Cavazzini F, Binotto G, Mansueto G, Russo S, Falzetti F, Montefusco E, Gugliotta G, Storti S, D'Addosio AM, Scaffidi L, Cortesi L, Cedrone M, Rossi AR, Avanzini P, Mauro E, Spadea A, Celesti F, Giglio G, Isidori A, Crugnola M, Calistri E, Sorà F, Rege-Cambrin G, Sica S, Luciano L, Galimberti S, Orlandi EM, Bocchia M, Tettamanti M, Alimena G, Saglio G, Rosti G, Mannucci PM, Cortelezzi A. Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. *Oncotarget* 2016;7(48):80083-80090.

Pieri L, Bonadonna P, Elena C, Papayannidis C, Grifoni FI, Rondoni M, Girlanda S, Mauro M, Magliacane D, Elli EM, Iorno ML, Almerigogna F, Scarfi F, Salerno R, Fanelli T, Gesullo F, Fattori GC, **Bonifacio M**, Perbellini O, Artuso A, Soverini S, De Benedittis C, Muratori S, Pravettoni V, Cova V, Cortellini G, Ciceri F, Cortelezzi A, Martinelli G, Triggiani M, Merante S, Vannucchi AM, Zanotti R. Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients. *Am J Hematol* 2016;91(7):692-699.

Maino E, **Bonifacio M**, Scattolin AM, Bassan R. Immunotherapy approaches to treat adult acute lymphoblastic leukemia. *Expert Rev Hematol* 2016;9(6):563-577.

Takam Kanga P, Bassi G, Cassaro A, Midolo M, Di Trapani M, Gatti A, Carusone R, Resci F, Perbellini O, Gottardi M, **Bonifacio M**, Nwabo Kamdje AH, Ambrosetti A, Krampera M. Notch signalling drives bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemia. *Oncotarget* 2016;7(16):21713-21727.

Bonadonna P, **Bonifacio M**, Lombardo C, Zanotti R. Hymenoptera allergy and mast cell activation syndrome. *Curr Allergy Asthma Rep* 2016;16(1):5.

Breccia M, Efficace F, Sica S, Abruzzese E, Cedrone M, Turri D, Gobbi M, Carella AM, Gozzini A, Usala E, Cavazzini F, Danise P, Tiribelli M, Binotto G, Pregno P, Bocchia M, Gaidano G, Crugnola M, **Bonifacio M**, Avanzini P, Celesti F, Guella A, Martino B, Annunziata M, Luciano L, Stagno F, Vallisa D, Pungolino E, Iurlo A, Rambaldi A, Nardiello I, Orlandi E, Gambacorti-Passerini C, Alimena G. Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. *Leuk Res.* 2015;39(10):1055-1059.

Bonadonna P, **Bonifacio M**, Lombardo C, Zanotti R. Hymenoptera anaphylaxis and C-kit mutations: an unexpected association. *Curr Allergy Asthma Rep* 2015;15(8):49.

Bonifacio M, Binotto G, Maino E, Calistri E, Marin L, Scaffidi L, Frison L, De Marchi F, Krampera M, Semenzato G, Fanin R, Ambrosetti A, and Tiribelli M. Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced possibility of subsequent optimal response. *Haematologica* 2015;100(8):e299-301.

Tiribelli M, Binotto G, Calistri E, Maino E, Scaffidi L, Medeot M, Nabergoj M, Ambrosetti A, Semenzato G, Fanin R, **Bonifacio M**. Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favourable response to frontline imatinib therapy. *Am J Hematol* 2015;90(7):e135-137.

Rossini M, Viapiana O, Zanotti R, Tripi G, Perbellini O, Idolazzi L, **Bonifacio M**, Adami S, Gatti D. Dickkopf-1 and Sclerostin serum levels in patients with Systemic Mastocytosis. *Calcif Tissue Int* 2015;96(5):410-416.

Arribas AJ, Rinaldi A, Mensah AA, Kwee I, Cascione L, Robles EF, Martinez-Climent JA, Oscier D, Arcaini L, Baldini L, Marasca R, Thieblemont C, Briere J, Forconi F, Zamò A, **Bonifacio M**, Mollejo M, Facchetti F, Dimhofer S, Ponzone M, Bhagat G, Piris MA, Gaidano G, Zucca E, Rossi D, Bertoni F. DNA methylation-profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. *Blood* 2015;125(12):1922-1931.

Zanotti R, Lombardo C, Passalacqua G, Caimmi C, **Bonifacio M**, De Matteis G, Perbellini O, Rossini M, Schena D, Busa M, Marcotulli MC, Bilò MB, Franchini M, Marchi G, Simioni L, Bonadonna P. Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels. *J Allergy Clin Immunol* 2015;136(1):135-139.

Castagnetti F, Gugliotta G, Baccarani M, Breccia M, Specchia G, Levato L, Abruzzese E, Rossi G, Iurlo A, Martino B, Pregno P, Stagno F, Cuneo A, **Bonifacio M**, Gobbi M, Russo D, Gozzini A, Tiribelli M, de Vivo A, Alimena G, Cavo M, Martinelli G, Pane F, Saglio G, Rosti G; on behalf of the GIMEMA CML Working Party. Differences among young adults, adults, and elderly chronic myeloid leukemia patients. *Ann Oncol* 2015;26(1):185-192.

De Matteis G, Zanotti R, Colarossi S, De Benedittis C, Garcia-Montero A, **Bonifacio M**, Sartori M, Aprili F, Caruso B, Paviati E, Carli G, Perbellini O, Zamò A, Bonadonna P, Pizzolo G, Guidi G, Martinelli G, Soverini S. The impact of sensitive KIT D816V detection on recognition of indolent systemic mastocytosis. *Leuk Res* 2015;39(3):273-278.

Pubblicazioni (continua)

Soverini S, De Benedittis C, Papayannidis C, Paolini S, Venturi C, Iacobucci I, Luppi M, Bresciani P, Salvucci M, Russo D, Sica S, Orlandi E, Intermesoli T, Gozzini A, **Bonifacio M**, Rigolin GM, Pane F, Baccarani M, Cavo M, Martinelli G. Drug resistance and BCR-ABL kinase domain mutations in philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: the main changes are in the type of mutations, but not in the frequency of mutation involvement. *Cancer* 2014;120(7):1002-1009.

Bonifacio M, Binotto G, Calistri E, Maino E, Tiribelli M for the Gruppo Triveneto LMC. EUTOS score predicts early optimal response to imatinib according to the revised 2013 ELN recommendations. *Ann Hematol* 2014;93(1):163-164.

Tiribelli M, **Bonifacio M**, Calistri E, Binotto G, Maino E, Marin L, Guardalben E, Branca A, Gherlinzoni F, Semenzato G, Sancetta R, Pizzolo G, Fanin R. EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukemia. *Leuk Res* 2013;37(11):1457-1460.

Chiaretti S, Brugnoletti F, Tavoraro S, Bonina S, Paoloni F, Marinelli M, Patten N, **Bonifacio M**, Kropp MG, Sica S, Guarini A, Foà R. TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy. *Haematologica* 2013;98:e59-61

Zanotti R, Simioni L, Garcia-Montero AC, Perbellini O, Bonadonna P, Caruso B, Jara-Acevedo M, **Bonifacio M**, De Matteis G. Somatic D816V mutation in a case of adult-onset familial mastocytosis. *J Allergy Clin Immunol* 2013;131(2):605-607.

Munari E, Rinaldi M, Ambrosetti A, **Bonifacio M**, Bonalumi A, Chilosi M, Zamò A. Absence of TCL1A expression is a useful diagnostic feature in splenic marginal zone lymphoma. *Virchows Arch* 2012;461(6):677-685.

Bonifacio M, Rigo A, Guardalben E, Bergamini C, Cavalieri E, Fato R, Pizzolo G, Suzuki H, Vinante F. α -bisabolol is an effective proapoptotic agent against BCR-ABL(+) cells in synergism with Imatinib and Nilotinib. *PLoS One* 2012;7(10):e46674.

Rigo A, Gottardi M, Damiani E, **Bonifacio M**, Ferrarini I, Mauri P, Vinante F. CXCL12 and [N33A]CXCL12 in 5637 and HeLa cells: regulating HER1 phosphorylation via calmodulin/calcineurin. *PLoS One* 2012;7(4):e34432.

Todeschini G, **Bonifacio M**, Tecchio C, Balter R, Carli G, Stefani PM, Adami F, Zamò A, Dei Tos AP, Marino F, Gherlinzoni F, Marradi P, Semenzato G, Pizzolo G. Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia. *Am J Hematol* 2012;87(1):22-25.

Rossini M, Zanotti R, Bonadonna P, Artuso A, Caruso B, Schena D, Vecchiato D, **Bonifacio M**, Viapiana O, Gatti D, Senna G, Riccio A, Passalacqua G, Pizzolo G, Adami S. Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. *Bone* 2011;49(4):880-885.

Cavalieri E, Rigo A, **Bonifacio M**, Carcereri de Prati A, Guardalben E, Bergamini C, Fato R, Pizzolo G, Suzuki H, Vinante F. Pro-apoptotic activity of α -bisabolol in preclinical models of primary human acute leukemia cells. *J Transl Med* 2011;9:45.

Zanotti R, Bonadonna P, **Bonifacio M**, Artuso A, Schena D, Rossini M, Perbellini O, Colarossi S, Chilosi M, Pizzolo G. Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis. *Haematologica* 2011;96(3):482-484.

Todeschini G, **Bonifacio M**, Tecchio C, Dalceggio D, Benedetti F, Gabbas A, Pizzolo G. A preliminary experience with the HyperCHiDAM Verona intensive chemotherapy regimen in heavily pretreated refractory Hodgkin's lymphoma. *Hematol Oncol* 2011;29(3):151-153.

Rigo A, Gottardi M, Zamò A, Mauri P, **Bonifacio M**, Krampera M, Damiani E, Pizzolo G, Vinante F. Macrophages may promote cancer growth via a GM-CSF/HB-EGF paracrine loop that is enhanced by CXCL12. *Mol Cancer* 2010;9:273.

Tecchio C, Colato C, **Bonifacio M**, Krampera M, Maluta S, Pizzolo G, Girolomoni G. Plasmacytoid dendritic cell leukemia: a rapidly evolving disease presenting with skin lesions sensitive to radiotherapy plus hyperthermia. *Oncologist* 2009;14:1205-1208.

Bonifacio M, Perbellini O, Pizzolo G. T-cell acute lymphoblastic leucemia and T-cell lymphoblastic lymphoma: therapy in adults. *Hematol Meeting Reports* 2009;3(1):115-122.

Stage di formazione internazionali

- Advanced course on Leukemia, presso M.D. Anderson Cancer Center, Houston (TX), 6-9/07/2009
- Stage presso Instituto de Mastocitosis de Castilla - La Mancha (ES), 11-15/04/2011

Autorizzo il trattamento dei dati personali contenuti nel mio curriculum vitae in base all'art. 13 del D. Lgs. 196/2003 e all'art. 13 del Regolamento UE 2016/679 relativo alla protezione delle persone fisiche con riguardo al trattamento dei dati personali.

Firma

A handwritten signature in black ink, appearing to read 'Bonifacio Massimiliano', written over a horizontal line.

12 nov 2024